Chinese Osteoporotic Fracture Registration Network Platform
NCT ID: NCT05339425
Last Updated: 2025-02-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
50000 participants
OBSERVATIONAL
2021-12-01
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Tiered Management System of Osteoporosis in China
NCT03916289
Multicenter Cohort Study on Osteoporosis
NCT02958020
Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture
NCT05866029
Prevalence and Predictors of Osteoporosis in the Beijing's Urban Population
NCT01476150
PRevention of OsTEoporotiC FracTure 2 Pilot Study
NCT06134908
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
About 100 hospitals covering 20 provinces, autonomous regions and municipalities will be selected as collaborators. Each collaborator is going to enroll at least 500 patients with osteoporotic fractures on average, and a total of 50000 subjects are planned to be enrolled in our study.
Subjects will be assessed as follows:
1. Questionnaire investigation: including demographic data, past medical history, reproductive history, menstrual/menopausal history, family history of osteoporosis and fractures, awareness of disease, diagnosis and treatment of osteoporotic fractures, etc.
2. Clinical features: including anthropometric data, clinical symptoms, physical examination, grip strength test, balance assessment, walking speed test, etc.
3. Fall risk assessment: assessed by the Short Physical Performance Battery (SPPB), the Falls Risk for Older People in the Community (FROP-Com) and Morse Fall Scale (MFS).
4. Imaging evaluation: including thoracolumbar spine x-ray, bone mineral density (BMD) measurement by dual-energy x-ray absorptiometry (DXA), Quantitative computed tomography (QCT) and high-resolution peripheral quantitative computed tomography (HR-pQCT).
5. Laboratory tests: including blood calcium and phosphorus levels, bone turnover markers, parathyroid hormone level, 25-hydroxyvitamin D, 24-hour urine calcium, etc.
6. Biological specimen collection: blood and urine specimens are plan to be obtained for further studies with informed consent.
7. Follow-ups: subjects will be followed up every 6 months for 3 years.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Osteoporotic fracture
No additional intervention will be administered.
No additional intervention will be administered.
No additional intervention will be administered.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No additional intervention will be administered.
No additional intervention will be administered.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with vertebral osteoporotic fracture.
* Patients with low T-score ( ≤ -2.5) and at least one risk factor (e.g., history of osteoporotic fractures in other sites, a parental history of hip fracture, age ≥ 65 years, BMI \< 18.5kg/m2, current smoking).
* Patients with very low T-score (\< -3.0).
* The ten year probability of fracture by FRAX: major osteoporosis fracture ≥20%, or hip fracture ≥3%.
Exclusion Criteria
* Patients judged as unqualified participants by clinicians.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Xuanwu Hospital, Beijing
OTHER
Beijing Hospital
OTHER_GOV
Tianjin First Central Hospital
OTHER
Hebei Medical University Third Hospital
OTHER
The Second Affiliated Hospital of Harbin Medical University
OTHER
Peking University Third Hospital
OTHER
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER
Ruijin Hospital
OTHER
Affiliated Hospital of Nantong University
OTHER
Shanghai Changzheng Hospital
OTHER
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
OTHER
Second Xiangya Hospital of Central South University
OTHER
Nanfang Hospital, Southern Medical University
OTHER
The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine
OTHER
First Affiliated Hospital of Fujian Medical University
OTHER
Second Affiliated Hospital of Guangzhou Medical University
OTHER
The Seventh Affiliated Hospital of Sun Yat-sen University
OTHER
Sichuan Province Orthopetic Hospital
OTHER
The Second Affiliated Hospital of Chongqing Medical University
OTHER
Daping Hospital, Army Medical Center of PLA
OTHER
First Affiliated Hospital Xi'an Jiaotong University
OTHER
The First Affiliated Hospital of Zhengzhou University
OTHER
Second Affiliated Hospital of Soochow University
OTHER
The First Affiliated Hospital with Nanjing Medical University
OTHER
Peking University Shenzhen Hospital
OTHER
General Hospital of Ningxia Medical University
OTHER
Second Affiliated Hospital of Wenzhou Medical University
OTHER
Beijing Jishuitan Hospital
OTHER
Zhejiang Hospital
OTHER
Shenzhen People's Hospital
OTHER
Xiangya Hospital of Central South University
OTHER
Beijing Friendship Hospital
OTHER
Shanghai 6th People's Hospital
OTHER
Shanghai East Hospital of Tongji University
OTHER
Zhongda Hospital
OTHER
First Affiliated Hospital of Jinan University
OTHER
Fujian Provincial Hospital
OTHER
Peking Union Medical College Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Weibo Xia, MD
Role: STUDY_CHAIR
Peking Union Medical College Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Beijing Hospital
Beijing, Beijing Municipality, China
Beijing Shijingshan Hospital
Beijing, Beijing Municipality, China
Peking University Third Hospital
Beijing, Beijing Municipality, China
The Second Medical Center of The General Hospital of the People's Liberation Army
Beijing, Beijing Municipality, China
Xuanwu Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Daping Hospital, Army Medical Center of PLA
Chongqing, Chongqing Municipality, China
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Fuzhou Second Hospital
Fuzhou, Fujian, China
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China
Lunjiao Hospital of Shunde Foshan
Foshan, Guangdong, China
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China
The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Guangzhou, Guangdong, China
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Shenzhen Second People's Hospital
Shenzhen, Guangdong, China
The Seventh Affiliated Hospital, Sun Yat-sen University
Shenzhen, Guangdong, China
Guizhou Provincial Orthopedics Hospital
Guiyang, Guizhou, China
The Third Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
The Second Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China
The First People's hospital of Changzhou
Changzhou, Jiangsu, China
Affiliated Hospital of Nantong University
Nantong, Jiangsu, China
Nantong First People's Hospital
Nantong, Jiangsu, China
The Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Dalian Hospital of Chinese Traditional and Western Medicine
Dalian, Liaoning, China
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
Shanghai Changzheng Hospital
Shanghai, Shanghai Municipality, China
Tenth People's Hospital of Tongji University
Shanghai, Shanghai Municipality, China
Sichuan Province Orthopedic Hospital
Chengdu, Sichuan, China
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China
West China Fourth Hospital, Sichuan University
Chengdu, Sichuan, China
Tianjin First Central Hospital
Tianjin, Tianjin Municipality, China
Traditional Chinese Medicine Hospital of Xinjiang Uygur Autonomous Region
Ürümqi, Xinjiang, China
The Second Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Huamei Hospital, University of Chinese Academy of Sciences
Ningbo, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021YFC2501701
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.